Quinalphos (CASRN 13593-03-8)
view QuickView

0189
Quinalphos; CASRN 13593-03-8
Health assessment information on a chemical substance is included in IRIS
only after a comprehensive review of chronic toxicity data by U.S. EPA
health scientists from several Program Offices and the Office of Research
and Development. The summaries presented in Sections I and II represent
a consensus reached in the review process. Background information and
explanations of the methods used to derive the values given in IRIS are
provided in the Background Documents.
STATUS OF DATA FOR Quinalphos
File First On-Line 03/31/1987
Category (section) |
Status |
Last Revised |
---|---|---|
Oral RfD Assessment (I.A.) | on-line | 01/01/1992 |
Inhalation RfC Assessment (I.B.) | no data | |
Carcinogenicity Assessment (II.) | no data |
_I. Chronic Health Hazard Assessments for Noncarcinogenic Effects
_I.A. Reference Dose for Chronic Oral Exposure (RfD)
Substance Name — Quinalphos
CASRN — 13593-03-8
Last Revised — 01/01/1992
The oral Reference Dose (RfD) is based on the assumption that thresholds
exist for certain toxic effects such as cellular necrosis. It is expressed
in units of mg/kg-day. In general, the RfD is an estimate (with uncertainty
spanning perhaps an order of magnitude) of a daily exposure to the human
population (including sensitive subgroups) that is likely to be without
an appreciable risk of deleterious effects during a lifetime. Please refer
to the Background Document for an elaboration of these concepts. RfDs
can also be derived for the noncarcinogenic health effects of substances
that are also carcinogens. Therefore, it is essential to refer to other
sources of information concerning the carcinogenicity of this substance.
If the U.S. EPA has evaluated this substance for potential human carcinogenicity,
a summary of that evaluation will be contained in Section II of this file.
__I.A.1. Oral RfD Summary
Critical Effect |
Experimental Doses* |
UF |
MF |
RfD |
---|---|---|---|---|
No adverse effects Two-year Feeding Dog Sandoz, Ltd., 1980a |
NOEL: 0.05 mg/kg/day LEL: none |
100
|
1
|
5E-4
mg/kg/day |
*Dose Conversion Factors & Assumptions: none
__I.A.2. Principal and Supporting Studies (Oral RfD)
Sandoz, Ltd. 1980a. MRID No. 00080571; HED Doc. No. 004976. Available from EPA. Write to FOI, EPA, Washington, DC 20460.
Quinalphos was administered in the diet at 0, 0.0025, 0.0125 or 0.05 mg/kg/day to 4 male and 4 female dogs/group for 2 years. Although there were no signs of systemic toxicity, plasma cholinesterase (P ChE) was decreased at 0.05 mg/kg/day. The NOEL for P ChE depression is 0.0125 mg/kg/day.
__I.A.3. Uncertainty and Modifying Factors (Oral RfD)
UF — The UF of 100 accounts for the inter- and intraspecies differences.
MF — None
__I.A.4. Additional Studies/Comments (Oral RfD)
None
Data Considered for Establishing the RfD:
1) 2-Year Feeding - dog: Principal study - see previous description; core grade minimum
2) 2-Year Feeding/Oncogenic - rat: Systemic NOEL=1.0 mg/kg/day; LEL not established; ChE NOEL = 0.15 mg/kg/day; LEL=1.0 mg/kg/day (decreased plasma and RBC ChE); core grade minimum (Sandoz, Inc., 1979a)
3) Teratology - rabbit: Maternal NOEL=4 mg/kg/day; LEL=8 mg/kg/day (decreased weight gain, ataxia, weakness, diarrhea); Fetotoxic NOEL=4 mg/kg/day; LEL=8 mg/kg/day (increased resorptions/litter); core grade minimum (Sandoz, Inc., 1979b)
4) Reproduction - rat: Maternal NOEL=0.5 mg/kg/day (HDT); LEL not established; Fetotoxic NOEL=0.5 mg/kg/day (HDT); LEL not established; ChE NOEL (Maternal and Pup)=0.15 mg/kg/day; ChE LEL=0.5 mg/kg/day (decreased RBC and plasma ChE); core grade minimum (Sandoz, Inc., 1980b)
Other Data Reviewed:
1) 18 month oncogenic - mouse: Systemic NOEL=0.075 mg/kg/day (HDT); LEL not established; ChE NOEL=0.03 mg/kg/day; LEL=0.15 mg/kg/day (decreased plasma ChE); core grade minimum (Sandoz, Inc., 1980c)
Data Gap(s): Rat Teratology
__I.A.5. Confidence in the Oral RfD
Study — High
Database — Medium
RfD — Medium
The principal study appears to be of good quality and is given a high confidence rating. The database on chronic toxicity is of fair quality; therefore, the database is given a medium confidence rating. Medium confidence in the RfD follows.
__I.A.6. EPA Documentation and Review of the Oral RfD
Pesticide Registration Files
Agency Work Group Review — 10/28/1986, 12/16/1986
Verification Date — 12/16/1986
Screening-Level Literature Review Findings — A screening-level review conducted by an EPA contractor of the more recent toxicology literature pertinent to the RfD for Quinalphos conducted in September 2002 identified one or more significant new studies. IRIS users may request the references for those studies from the IRIS Hotline at hotline.iris@epa.gov or (202)566-1676.
__I.A.7. EPA Contacts (Oral RfD)
Please contact the IRIS Hotline for all questions concerning this assessment or IRIS, in general, at (202)566-1676 (phone), (202)566-1749 (FAX) or hotline.iris@epa.gov (internet address).
_I.B. Reference Concentration for Chronic Inhalation Exposure (RfC)
Substance Name — Quinalphos
CASRN — 13593-03-8
Not available at this time.
_II. Carcinogenicity Assessment for Lifetime Exposure
Substance Name — Quinalphos
CASRN — 13593-03-8
This substance/agent has not undergone a complete evaluation and determination under US EPA's IRIS program for evidence of human carcinogenic potential.
_III.
[reserved]
_IV. [reserved]
_V. [reserved]
_VI. Bibliography
Substance Name — Quinalphos
CASRN — 13593-03-8
Last Revised — 01/01/1992
_VI.A. Oral RfD References
Sandoz, Ltd. 1979a. MRID No. 00084267; HED Doc. No. 004976. Available from EPA. Write to FOI, EPA, Washington, DC 20460.
Sandoz, Ltd. 1979b. MRID No. 00081691; HED Doc. No. 004976. Available from EPA. Write to FOI, EPA, Washington, DC 20460.
Sandoz, Ltd. 1980a. MRID No. 00080571; HED Doc. No. 004976. Available from EPA. Write to FOI, EPA, Washington, DC 20460.
Sandoz, Ltd. 1980b. MRID No. 00081690; HED Doc. No. 004976. Available from EPA. Write to FOI, EPA, Washington, DC 20460.
Sandoz, Ltd. 1980c. MRID No. 00081689; HED Doc. No. 004976. Available from EPA. Write to FOI, EPA, Washington, DC 20460.
_VI.B. Inhalation RfC References
None
_VI.C. Carcinogenicity Assessment References
None
_VII. Revision History
Substance Name — Quinalphos
CASRN — 13593-03-8
Date |
Section |
Description |
---|---|---|
01/01/1992 | I.A.4. | Citations added |
01/01/1992 | VI. | Bibliography on-line |
04/01/1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
12/03/2002 | I.A.6. | Screening-Level Literature Review Findings message has been added. |
_VIII. Synonyms
Substance Name — Quinalphos
CASRN — 13593-03-8
Last Revised — 03/31/1987
- 13593-03-8
- BAY 5821
- BAY 77049
- BAYRUSIL
- CHINALPHOS
- DIETHQUINALPHION
- DIETHQUINALPHIONE
- EKALUX
- ENT 27394
- NSC 190986
- O,O-DIAETHYL-O-(CHINOXALYL-(2))-MONOTHIOPHOSPHAT
- O,O-DIETHYL O-(2-CHINOXALYL)-PHOSPHOROTHIOATE
- O,O-DIETHYL O-QUINOXALIN-2-YL PHOSPHOROTHIOATE
- O,O-DIETHYL-O-(2-QUINOXALYL) PHOSPHOROTHIOATE
- O,O-DIETHYL-O-2-QUINOXALYL-THIOPHOSPHATE
- PHOSPHOROTHIOIC ACID, O,O-DIETHYL O-(2-QUINOXALINYL) ESTER
- Quinalphos
- S-6538
- SAN 6538 I
- SAN 6626 I
- SANDOZ 6538
- SPENCER S-6538
- SRA 7312
- WIE OBEN